Tim Lugo
Stock Analyst at William Blair
(0.45)
# 4,017
Out of 4,884 analysts
23
Total ratings
33.33%
Success rate
-28.45%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Lugo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Downgrades: Market Perform | n/a | $57.50 | - | 3 | Oct 30, 2024 | |
| APLT Applied Therapeutics | Initiates: Outperform | n/a | $0.32 | - | 1 | Jul 31, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | n/a | $32.53 | - | 1 | Apr 15, 2024 | |
| SLDB Solid Biosciences | Initiates: Outperform | $40 | $5.03 | +695.23% | 1 | Mar 28, 2024 | |
| ZVRA Zevra Therapeutics | Initiates: Outperform | n/a | $9.74 | - | 1 | Mar 12, 2024 | |
| ABBV AbbVie | Upgrades: Outperform | n/a | $189.28 | - | 2 | Jan 29, 2024 | |
| ACRS Aclaris Therapeutics | Downgrades: Market Perform | n/a | $1.44 | - | 1 | Nov 13, 2023 | |
| TVTX Travere Therapeutics | Downgrades: Market Perform | n/a | $15.01 | - | 1 | Sep 21, 2023 | |
| SPRY ARS Pharmaceuticals | Downgrades: Market Perform | n/a | $16.52 | - | 2 | Sep 20, 2023 | |
| VTGN Vistagen Therapeutics | Downgrades: Market Perform | n/a | $2.00 | - | 3 | Jul 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $62 | $9.20 | +573.91% | 1 | Jun 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.74 | - | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $33.26 | - | 1 | Jan 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.17 | - | 2 | Sep 22, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.34 | - | 1 | May 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $46 | $14.63 | +214.42% | 1 | May 30, 2017 |
BioMarin Pharmaceutical
Oct 30, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $57.50
Upside: -
Applied Therapeutics
Jul 31, 2024
Initiates: Outperform
Price Target: n/a
Current: $0.32
Upside: -
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $32.53
Upside: -
Solid Biosciences
Mar 28, 2024
Initiates: Outperform
Price Target: $40
Current: $5.03
Upside: +695.23%
Zevra Therapeutics
Mar 12, 2024
Initiates: Outperform
Price Target: n/a
Current: $9.74
Upside: -
AbbVie
Jan 29, 2024
Upgrades: Outperform
Price Target: n/a
Current: $189.28
Upside: -
Aclaris Therapeutics
Nov 13, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.44
Upside: -
Travere Therapeutics
Sep 21, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $15.01
Upside: -
ARS Pharmaceuticals
Sep 20, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $16.52
Upside: -
Vistagen Therapeutics
Jul 22, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.00
Upside: -
Jun 16, 2021
Downgrades: Market Perform
Price Target: $62
Current: $9.20
Upside: +573.91%
Nov 24, 2020
Initiates: Outperform
Price Target: n/a
Current: $3.74
Upside: -
Jan 8, 2020
Initiates: Outperform
Price Target: n/a
Current: $33.26
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $1.17
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $0.34
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: $46
Current: $14.63
Upside: +214.42%